Capmatinib Effective with Manageable Safety in METex14 NSCLC, Including Brain Metastases
The following is a summary of “Capmatinib efficacy for METex14 non-small cell lung cancer patients: Results of the IFCT-2104 CAPMATU study,” published in the August 2024 issue of Pulmonology by Ferreira et al. Capmatinib, a selective MET inhibitor, has demonstrated...